Aarti Drugs Limited · NSE:AARTIDRUGS
Aarti Drugs — H1 FY26 Earnings Presentation
41 slides from Aarti Drugs's earnings presentation, Nov 7, 2025
Slide 1: Stock exchange filing cover letter
Ref: ADL/SE/2025-26/54 November 7, 2025 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East),
Slide 2: Q2 & H1 FY26 Investor Presentation
Aarti Drugs Limited Q2 & H1 FY26 Investor Presentation November 2025
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Aarti Drugs Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securitie
Slide 4: Table of Contents
01 Q2 & H1 FY26 Business & Financial Highlights 04 02 Company & Business Overview 08 Table of Contents 03 Industry Overview 21 04 Key Strengths & Growth Drivers 24 05 Historical Financial Performance 31 3
Slide 5: Q2 & H1 FY26 Business & Financial Highlights
Q2 & H1 FY26 Business & Financial Highlights
Slide 6: Q2 & H1 FY26 Consolidated Financial Highlights
Q2 & H1 FY26 Consolidated Financial Highlights Total Revenue EBITDA & EBITDA Margin PAT & PAT Margin (Rs. Crs.) (Rs. Crs.) (Rs. Crs.) 11.4% 12.9% 5.8% 6.9% +9% 653 +23% +29% 600 84 45 69 35 Q2 FY25 Q2 FY26 Q2 FY25 Q2 FY26 Q2 FY25 Q2 FY26 11.6% 12.8% 5.9% 8.0% +8% 1,244 +18% +45% 1,156 159 99 135 68
Slide 7: Q2 & H1 FY26 Segment Breakup
Q2 & H1 FY26 Segment Breakup Segmental Revenue Therapeutic-wise Revenue* (Within API Segment) 12.6% 5.7% Anti-biotic 11.8% 15.3% 2.6% API Anti-protozoal Formulation Anti-inflammatory 11.7% Speciality Chemicals 18.8% Anti-diabetic Q2 FY26 Intermediates & Others Q2 FY26 Anti-fungal 6.4% Others 79.0% 3
Slide 8: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. Crs.) Q2 FY26 Q2 FY25 YoY Change Q1 FY26 QoQ Change H1 FY26 H1 FY25 YoY Change Net Revenue from Operations 652.8 598.3 9% 590.5 11% 1,243.3 1,153.7 8% Other Income 0.1 1.5 0.3 0.4 2.6 Total Revenue 652.9 599.8 9% 590.8 11% 1,243.7 1,156.3 8% COGS
Slide 9: Consolidated Balance Sheet
Consolidated Balance Sheet Equity & Liabilities (Rs. Crs.) Sep-25 Mar-25 Assets (Rs. Crs.) Sep-25 Mar-25 Equity Non-Current assets Equity Share capital 91.3 91.3 Property, Plant and Equipment 1,066.3 856.3 Other Equity 1,377.0 1,277.7 Capital work in progress 179.1 330.2 Non-Controlling Interest 0.3
Slide 10: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. Crs.) Sep-25 Sep-24 Net Profit before Tax and Extraordinary items 111.5 89.9 Adjustments for: Non Cash Items / Other Investment or Financial Items 49.6 46.7 Operating profit before working capital changes 161.1 136.6 Changes in working capital -9.0 5
Slide 11: Management Commentary
Management Commentary Commenting on the results, Mr. Adhish Patil, CFO & COO, of Aarti Drugs Limited said, “We are pleased with the operational progress achieved during the quarter. Aarti Drugs posted revenue of Rs. 652.9 crore in Q2 FY26, growing 9% year-on-year, with EBITDA of Rs. 84.4 crore, up 2
Slide 12: Company & Business Overview
Company & Business Overview Aarti Drugs Ltd.
Slide 13: Leadership in API Manufacturing
Leadership in API Manufacturing Over a decade, API manufacturing has transitioned towards highly regulated, specialized business 14 5,088 1 Largest producer of Nimesulide in the world Manufacturing Facilities MT/Monthly Capacity 2 Largest producer of Ketoconazole in the world 80+ 50+ 3 Largest produ
Slide 14: Diversified Presence across Segments
Diversified Presence across Segments Presence Across APIs, Formulation, Specialty Chemicals, Intermediates Segments Active Pharmaceuticals Ingredients (API) Formulations Specialty Chemicals, Intermediates & Others ✓ Leading API producer with 50+ molecules across ✓ Diversified into formulations in 20
Slide 15: Diversified Product & Client Mix
Diversified Product & Client Mix Presence across Segments, Geographies, API Therapies & Customers to ensure Growth and Risk Minimization ▪ Domestic - Export mix at 63% for FY25 ▪ API business contributes 81% of sales in FY25 Geographic ▪ Presence across 100+ countries Segmental ▪ Focus on increasing
Slide 16: Journey
Journey 2024 Forayed into the personal care segment with the commissioning of a greenfield project for 2021 dermatology products at Tarapur Surpassed a consolidated turnover of 2025 Rs. 2,000 Crores Capex for Greenfield project Pinnacle Life Science Private Limited at Sayakha, Gujarat & surpassed a
Slide 17: Manufacturing Footprint
Manufacturing Footprint Baddi Pinnacle Plant Formulation Plant WHO-GMP ✓ The capacity of Multi- Sarigam-1 purpose plant ranges from kilograms to multi tons levels WHO-GMP Sarigam-2 ✓ Long term experience of WHO-GMP/ Multi-step synthesis and COFEPRIS/CEP fractionations at high temperatures Sayakha WH
Slide 18: Diversified Geographic Presence
Diversified Geographic Presence North America Europe 8% 11% 14% 12% FY24 FY25 FY24 FY25 Egypt Asia Latin America Türkiye Pakistan 57% 52% 10% 14% Bangladesh FY24 FY25 FY24 FY25 Switzerland Mexico UAE Nigeria Market Segmentation Africa Indonesia 11% 11% Brazil 34% FY24 FY25 FY25 Top 10 Export Destina
Slide 19: Our Esteemed Clientele
/ Our Esteemed Clientele => AB Aarti Drugs Ltd. we wei INTAS) ©) Abbott (@ LABORATE imdioce (INTAS) so @ Cipla Mankindill 7 9S Weary mn WO fankindll> Kopran SUN Zydus Alombics © E LUPIN NB 4ortent dus lembic. 8 lorrery Cadila menue ‘ev LUPIN 4 PHARMA Pfizer, SANOFI 18
Slide 20: Our Vision & Mission
Our Vision & Mission To be the Preferred Global Supplier of Bulk Drugs by: To achieve global market ✓ Ensuring consistent quality, timely leadership by: delivery, and competitive pricing ✓ Driving product growth and ✓ Offering customized, customer- innovation centric solutions ✓ Fostering a winning
Slide 21: Key Executive Management
Key Executive Management Shri Chandrakant V. Gogri Shri Rashesh C. Gogri Chairman Emeritus Shri Prakash M. Patil Managing Director Chairman, MD & CEO • One of the Founder Promoters of the Company • • Has over 25 years of experience in the chemical & Brings over 21 years of experience in Production,
Slide 22: Independent Directors
Independent Directors Shri Ankit V. Paleja Smt. Neha R. Gada Shri Sandeep M. Joshi Independent Director Independent Director Independent Director • A qualified lawyer with 16 years of legal experience • Chartered Accountant and certified Insolvency Professional • Holds a Chemistry degree from Mumbai
Slide 23: ESG Initiatives
ESG Initiatives E • Zero Liquid Discharge (ZLD) • Carbon Footprint Reduction • Eco-friendly Packaging • Efficient Utilities & Green Technologies Environment S • Healthcare Initiatives • Woman Empowerment • Fair Trade Practices • Gender Diversity Social G • Stakeholder Responsibility • Risk Managemen
Slide 24: Awards and Accolades
Awards and Accolades 1991 2001 2005-06 2009 2012 CHEMEXCIL CHEMEXCIL Outstanding Performance in AVAYA GLOBAL CHEMEXCIL CHEMEXCIL Outstanding Performance Export, Organization of CONNECT Outstanding Performance Outstanding Performance in Export Pharmaceutical Product, Customer Responsiveness in Export
Slide 25: Industry Overview
Industry Overview Aarti Drugs Ltd.
Slide 26: Indian Pharmaceutical Industry
Indian Pharmaceutical Industry Indian Pharmaceutical Market Value (in USD Bn) 20% India’s Contribution to global generic drug exports India produces (FY25) 60,000+ generics +7.5% 425 drugs across 60 API market (third largest therapeutic +17.8% 125 8% share globally in FY25) categories and 55 supplie
Slide 27: Multiple Triggers will lead to high Growth Momentum
Multiple Triggers will lead to high Growth Momentum ▪ Rising domestic population ▪ 100% FDI in the pharmaceutical sector under Robust ▪ Higher Insurance Coverage penetration automatic route Increased Domestic Investments Demand ▪ Increased government spending on hospitals and healthcare ▪ Artificial
Slide 28: Key Strengths & Growth Drivers
Key Strengths & Growth Drivers
Slide 29: Unique Competitive Position
Unique Competitive Position Long-term relationship; repeat Economies of Scale Good Purchasing Power business from customers 4 decades of experience Strong International Superior Quality Client Diversification presence Less regional dependence Process Phase-Wise Capex to Known brand in improvement R&
Slide 30: Aarti Drugs is well poised to overcome industry challenges
Aarti Drugs is well poised to overcome industry challenges Specialized player in the highly challenging Pharmaceutical Industry Aarti Drug’s Core Competencies Industry’s Unique Challenges ✓ Demonstrated manufacturing excellence for 4 decades ✓ High R&D costs ✓ R&D focused, driven by continuous impro
Slide 31: Capex of Rs. 600 crores nearly complete; Boosting capacity, margins
Capex of Rs. 600 crores nearly complete; Boosting capacity, margins Anti-diabetics Antiprotozoals Formulations Anti-inflammatory Operational Scale-up at ✓ With a manufacturing capacity ✓ Enhancing the position in ✓ Commenced commercial ✓ Targeting highly Tarapur Greenfield exceeding 1,450 TPM, ADL i
Slide 32: Product Pipeline
Product Pipeline As of 31-Mar-25 API Finished Dosages Product Under Development Product Under Development Product Under Development: LATAM & : New Age Molecules For Emerging Markets Anti Fungal regulated Markets Anti-Diabetic 2 Anti Diabetic 1 3 1 1 Anti-Protozol Anti Inflammatory 4 1 1 Carboxylatio
Slide 33: Strong R&D thrust on continuous innovation
Strong R&D thrust on continuous innovation • Supports manufacturing facilities at Tarapur and Sarigam on API process development 2 • Pilot plant used for kilo scale manufacturing R&D Center at Tarapur Doctorates • Recognized by Department by Science and Industrial Research (DSIR) Government of India
Slide 34: Robust Balance Sheet
Robust Balance Sheet Net Operating Cashflow Debt to Equity Profile (in Rs. Crore) (in Rs. Crore) 359 1,369 1,400 0.60 0.6 0.52 0.51 1,282 1,193 0.44 0.45 1,200 0.38 0.4 1,036 251 245 1,000 0.2 913 800 0.0 653 615 155 609 134 600 538 564 -0.2 400 372 344 -0.4 70 200 -0.6 0 -0.8 FY20 FY21 FY22 FY23 FY
Slide 35: Historical Financial Performance
Historical Financial Performance
Slide 36: Historical Consolidated Performance
Historical Consolidated Performance Total Revenue EBITDA & EBITDA Margin PAT & PAT Margin Earnings Per Share (in Rs. Crore) (in Rs. Crore) (in Rs. Crore) (in Rs.) 20.5% 13.7% 11.3% 12.7% 12.6% 13.0% 8.2% 6.1% 6.8% 7.0% 2,718 442 280 30.1 2,500 2,533 2,403 2,159 341 22.1 308 321 303 205 166 172 168 1
Slide 37: Historical Profit & Loss Statement
Historical Profit & Loss Statement Particulars (Rs. Crore) FY25 FY24 FY23 FY22 FY21 Net Revenue from Operations 2,387.0 2,528.6 2,716.1 2,488.6 2,154.8 Other Income 16.4 4.0 2.2 11.3 4.5 COGS 1,542.1 1,677.7 1,888.5 1,688.8 1,321.0 Gross Profit 861.3 854.9 829.8 811.1 838.3 Gross Margin (%) 36.1% 33
Slide 38: Consolidated Balance Sheet
Consolidated Balance Sheet Equities & Liabilities (Rs. Crore) Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Assets (Rs. crores) Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Equity Non Current assets Equity Share capital 91.3 91.9 92.6 92.6 93.2 Property, Plant and Equipment 856.3 808.2 673.2 685.7 659.2 Other Equity 1,2
Slide 39: Consolidated Cash Flow statement
Consolidated Cash Flow statement Particulars (Rs. Crore) FY25 FY24 FY23 FY22 FY21 Net Profit before Tax and Extraordinary items 211.8 235.5 224.2 270.0 369.0 Adjustments for: Non Cash Items / Other Investment or Financial Items 84.3 83.0 85.2 70.4 68.6 Operating profit before working capital changes
Slide 40: Rewarding Shareholders over time
Rewarding Shareholders over time Distributed ~Rs. 69.48 Crore as Distribution Policy Dividend over last 7 years Considering various financial Distributed ~ Rs. 278 Crore in parameters, the Company may form of dividend & buyback of shares over last 7 years elect to distribute ~15% to 30% Distributed
Slide 41: Thank You
Thank You Company: Aarti Drugs Limited CIN: L37060MH1984PLC055433 Mr. Rushikesh Deole investorrelations@aartidrugs.com / +91 22 24048199 www.aartidrugs.co.in Investor Relations: Strategic Growth Advisors (SGA) CIN: U74140MH2010PTC204285 Mr. Deven Dhruva / Ms. Krisha Shrimankar deven.dhruva@sgapl.net